S. Korea’s Binex invests in CAR-T therapy developer PeproMene Bio in US – pulse
pulse |
S. Korea’s Binex invests in CAR–T therapy developer PeproMene Bio in US
pulse Binex Co., South Korea’s biomedicines developer and contract manufacturing organization (CMO), has invested $10 million in PeproMene Bio Inc., a U.S.-based developer of novel immune-oncology therapies such as chimeric antigen receptor T cell (CAR-T … |
WCVB Boston |
Groundbreaking gene therapy used in momentous vision surgery
WCVB Boston “At night I have really bad reaction time,” he said. “Probably around 6 p.m. I’ll go inside and I can’t see outside at all.” Jack has a rare gene mutation that makes him unable to see peripherally, or in dim light. For a kid who just wants to play … |